US equities |
INTC $65.44 ▼-28.93% AMZN $238.03 ▼-2.36% MU $900.66 ▼-3.60% NVDA $207.75 ▼-2.77% SNDK $1,223.80 ▼-7.99% GOOGL $281.29 ▼-0.89% AMD $515.99 ▼-8.90% TSLA $397.04 ▼-1.55%
FinancialContent

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

8.350 -1.210 (-12.66%)
Delayed Quote Updated: 10:04 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
24 25 Next >
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
Just be ready to ride out some inevitable turbulence along the way. 
Via The Motley Fool
News headline image
Peering Into Iovance Biotherapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Is Iovance Biotherapeutics Stock a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back ↗
Via The Motley Fool
News headline image
A Peek at Iovance Biotherapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
2 Innovative Stocks That Could Deliver Outsize Returns ↗
Via The Motley Fool
News headline image
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Is Iovance Biotherapeutics Stock a Buy? ↗
The biotech is making important breakthroughs, but is that enough? 
Via The Motley Fool
News headline image
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Looking Into Iovance Biotherapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Stock Triumphed on Thursday ↗
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout. 
Via The Motley Fool
News headline image
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow ↗
This biotech's growth story is going to start moving faster, and soon. 
Via The Motley Fool
News headline image
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today ↗
There's plenty of upside with this stock, but it might take a while to realize. 
Via The Motley Fool
News headline image
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio? ↗
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile. 
Via Benzinga
Topics Artificial Intelligence
News headline image
This Is the Biggest Risk With Iovance Biotherapeutics Stock ↗
Investors should brace for dilution. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
3 Monster Biotech Stocks to Buy Before 2025 ↗
These companies are nearly in the sweet spot of risk versus reward in biotech. 
Via The Motley Fool
News headline image
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? ↗
This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock ↗
It could demonstrate a few capabilities that no other biotech has as of yet. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Shares Are Soaring Today ↗
The biopharma company is proving its recently approved cancer therapy is marketable. 
Via The Motley Fool
News headline image
Why Is Iovance Bio (IOVA) Stock Up 18% Today? ↗
Iovance Biotherapeutics stock is gaining as IOVA investors react to strong Q2 earnings beats and positive guidance for 2024 and 2025. 
Via InvestorPlace
Topics Earnings
News headline image
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges ↗
Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
24 25 Next >